Cingulate Inc. (CING)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment.
Cingulate Inc. (CING) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cingulate Inc. ever had a stock split?
Cingulate Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer L. Callahan CPA CEO | NASDAQ (CM) Exchange | 17248W105 CUSIP |
| US Country | 13 Employees | - Last Dividend | 9 Aug 2024 Last Split | 8 Dec 2021 IPO Date |
Overview
Cingulate Inc. is a biopharmaceutical entity concentrated on pioneering pharmaceutical interventions for the management of attention deficit/hyperactivity disorder (ADHD) and anxiety within the United States. The innovative trajectory of this company, since its inception in 2012, has been toward addressing the nuanced needs in the treatment paradigms of ADHD and anxiety among diverse age groups. With its base of operations anchored in Kansas City, Kansas, Cingulate Inc. delineates a vivid illustration of a committed pursuit towards enhancing therapeutic options with a foundational emphasis on stimulant medications tailored for ADHD alongside exploring avenues for anxiety treatments.
Products and Services
-
CTx-1301 (Dexmethylphenidate)
Occupying a pivotal stance in Cingulate Inc.'s product pipeline, CTx-1301 embarks on a progressive phase 3 clinical trial phase. This manifestation of dexmethylphenidate underlines the company's strategic initiative to cater to the ADHD community. CTx-1301 reflects an evolved therapeutic option, aiming to mitigate the symptoms of ADHD, fostering an improved quality of life for children, adolescents, and adults grappling with this condition.
-
CTx-1302 (Dextroamphetamine)
Progressing through the investigational new drug application development phase, CTx-1302 unveils another spectrum of Cingulate Inc.'s dedication toward ADHD treatment. Embodying dextroamphetamine, this product is poised to anchor a significant role in advancing ADHD management. The developmental trajectory of CTx-1302 is emblematic of a holistic approach, intending to encompass an extensive demographic inclusivity encompassing children to adults.
-
CTx-2103
Enriching the diversity of Cingulate Inc.'s pharmaceutical catalog, CTx-2103 steps into the formulation stage with a keen focus on anxiety relief. This initiative underlines an expansive vision, transcending beyond the ADHD spectrum to address anxiety. CTx-2103 embodifies the company's forward-thinking ethos, laying foundational stones towards offering a therapeutic recourse for individuals navigating through the complexities of anxiety disorders.
Contact Information
